BioXcel Therapeutics Inc (NASDAQ:BTAI) has a beta value of -0.03 and has seen 2.11 million shares traded in the last trading session. The BTAI stock price is -917.07% off its 52-week high price of $4.17 and 12.2% above the 52-week low of $0.36. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.86 million shares traded. The 3-month trading volume is 623.54K shares.
The consensus among analysts is that BioXcel Therapeutics Inc (BTAI) is Buy stock at the moment, with a recommendation rating of 1.50. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 8 have rated it as a Hold, with 7 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.31.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BioXcel Therapeutics Inc (NASDAQ:BTAI) trade information
Sporting -1.38% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the BTAI stock price touched $0.41 or saw a rise of 21.15%. Year-to-date, BioXcel Therapeutics Inc shares have moved -86.22%, while the 5-day performance has seen it change -14.71%. Over the past 30 days, the shares of BioXcel Therapeutics Inc (NASDAQ:BTAI) have changed -21.91%. Short interest in the company has seen 0.35 million shares shorted with days to cover at 0.93.
Wall Street analysts have a consensus price target for the stock at $1, which means that the shares’ value could jump 59.0% from current levels. The projected low price target is $1.0 while the price target rests at a high of $1.0. In that case, then, we find that the current price level is -143.9% off the targeted high while a plunge would see the stock gain -143.9% from current levels.
BioXcel Therapeutics Inc (BTAI) estimates and forecasts
Figures show that BioXcel Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -69.44% over the past 6 months, with this year growth rate of 70.73%, compared to 16.90% for the industry. Revenue growth from the last financial year stood is estimated to be 175.66%.
5 analysts offering their estimates for the company have set an average revenue estimate of 1.24M for the current quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -35.97% over the past 5 years.
BTAI Dividends
BioXcel Therapeutics Inc is expected to release its next earnings report in January this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
BioXcel Therapeutics Inc (NASDAQ:BTAI)’s Major holders
Insiders own 20.06% of the company shares, while shares held by institutions stand at 8.76% with a share float percentage of 10.96%. Investors are also buoyed by the number of investors in a company, with BioXcel Therapeutics Inc having a total of 72.0 institutions that hold shares in the company. The top two institutional holders are ARMISTICE CAPITAL, LLC with over 2.99 million shares worth more than $3.82 million. As of 2024-06-30, ARMISTICE CAPITAL, LLC held 9.6767% of shares outstanding.
The other major institutional holder is FMR LLC, with the holding of over 2.21 million shares as of 2024-06-30. The firm’s total holdings are worth over $2.82 million and represent 7.1439% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund . As of Sep 30, 2024 , the former fund manager holds about 2.07% shares in the company for having 886.25 shares of worth $0.36 million while later fund manager owns 293.32 shares of worth $0.12 million as of Sep 30, 2024 , which makes it owner of about 0.69% of company’s outstanding stock.
